

## 2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

Sivextro

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: 🛛 Exchange - PA	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	Specialty/facility name (if applicable):

REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.		
Q1. Is the patient 12 years of age or old	ler?	
□ Yes	□ No	
Q2. Is the patient pregnant or of childbearing age?		
□ Yes	□ No	
Q3. Has the patient been counseled on the potential risks to a fetus?		
□ Yes	□ No	
Q4. Does the patient have a proven diagnosis of a Gram-positive bacterial skin and/or subcutaneous tissue infection that is susceptible to Sivextro? Susceptible microorganisms include: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis. Documentation must be attached.		
□ Yes	□ No	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



F

## 2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

Sivextro

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.		
Patient Name:	Prescriber Name:	
Q5. Have both labs (sensitivities and cultures/blood culture results) and an Infectious Disease consult been completed? Documentation must be attached.		
□ Yes	□ No	
<ul> <li>Q6. Is the patient intolerant to, unable to take or tried and failed clinically appropriate pharmacological treatment based on lab results (sensitivities and cultures/blood culture results) and local resistance patterns? Documentation must be attached. Pharmacological treatment includes the following: <ul> <li>a. Clindamycin by mouth</li> <li>b. Trimethoprim-sulfamethoxazole by mouth</li> <li>c. Doxycycline by mouth or minocycline by mouth</li> <li>d. Ciprofloxacin by mouth</li> <li>e. Linezolid by mouth</li> <li>f. Cetriaxone intravenously</li> <li>g. Vancomycin intravenously</li> <li>h. Daptomycin intravenously</li> </ul> </li> </ul>		
□ Yes	□ No	
Q7. Does the patient have a diagnosis of neutropenia defined as neutrophil counts <1000 cells/mm? Labs must be attached.		
□ Yes	□ No	
Q8. Additional Information:		

Prescriber Signature

Date 2024 Prior Authorization Request

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document